Does Mounjaro Help You Lose Weight? The Clinical Evidence and What 72-Week Trial Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) produces 15% to 22.5% total body weight loss at 72 weeks in clinical trials, making it the most effective weight-loss medication currently available
• The mechanism combines GLP-1 and GIP receptor activation to suppress appetite, slow gastric emptying, and improve insulin sensitivity
• Weight loss follows a predictable three-phase pattern: rapid initial loss (weeks 1-12), steady plateau (weeks 12-40), and maintenance (weeks 40-72)
• About 89% of patients on the 15 mg dose achieve at least 5% weight loss, and 57% achieve 20% or more, compared to 3% on placebo

Direct answer (40-60 words)

Yes. Mounjaro (tirzepatide) produces clinically significant weight loss in both diabetes and obesity populations. In the SURMOUNT-1 trial, patients without diabetes lost an average of 22.5% of their body weight at 72 weeks on the 15 mg dose. Patients with type 2 diabetes in the SURPASS trials lost 12% to 15% on average. Both outcomes exceed all prior weight-loss medications.

Table of contents

1. The clinical trial evidence: SURMOUNT and SURPASS data
2. How tirzepatide produces weight loss: the dual-agonist mechanism
3. The three-phase weight loss pattern and what to expect week by week
4. Who responds best: predictors of high vs low response
5. Mounjaro vs semaglutide: head-to-head comparison
6. What most articles get wrong about the 22.5% figure
7. The dose-response relationship: does higher dose mean more weight loss?
8. Plateau management: why weight loss stalls and how to restart it
9. When Mounjaro doesn't work: the three failure modes
10. Maintenance after goal weight: staying on vs tapering off
11. Real-world outcomes vs clinical trial results
12. FAQ

The clinical trial evidence: SURMOUNT and SURPASS data

The question "does Mounjaro help you lose weight" has been answered definitively by two large trial programs: SURMOUNT (obesity without diabetes) and SURPASS (type 2 diabetes).

SURMOUNT-1 enrolled 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, but without diabetes. Participants received tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks, plus lifestyle counseling.

Dose	Average weight loss	% achieving ≥5% loss	% achieving ≥20% loss	Placebo-adjusted difference
Placebo	3.1%	35%	3%	-
5 mg	15.0%	85%	30%	11.9%
10 mg	19.5%	89%	50%	16.4%
15 mg	22.5%	91%	57%	19.4%

The 22.5% average at 15 mg translates to 52 pounds lost for a 230-pound person. This is the highest weight loss ever recorded in a pharmaceutical trial without surgical intervention (Jastreboff et al., New England Journal of Medicine, 2022).

SURMOUNT-2 enrolled 938 adults with obesity and type 2 diabetes. Weight loss was lower than SURMOUNT-1 but still substantial:

Dose	Average weight loss	% achieving ≥5% loss
Placebo	3.2%	34%
10 mg	13.4%	79%
15 mg	15.7%	83%

The diabetes population loses less weight because insulin resistance and metabolic dysfunction make weight loss harder, not because tirzepatide works differently (Garvey et al., Lancet, 2023).

SURPASS-2 was a head-to-head comparison of tirzepatide vs semaglutide 1 mg in 1,879 adults with type 2 diabetes. Weight loss at 40 weeks:

Treatment	Average weight loss
Semaglutide 1 mg	5.7%
Tirzepatide 5 mg	7.6%
Tirzepatide 10 mg	9.3%
Tirzepatide 15 mg	11.2%

Tirzepatide beat semaglutide at every dose comparison (Frías et al., New England Journal of Medicine, 2021). The SURPASS-2 data is the reason tirzepatide is considered the most effective GLP-1-class medication currently available.

How tirzepatide produces weight loss: the dual-agonist mechanism

Mounjaro's active ingredient is tirzepatide, a dual GLP-1 and GIP receptor agonist. It's the only medication in clinical use that activates both receptors. Understanding the mechanism explains why it outperforms single-agonist drugs like semaglutide.

GLP-1 receptor activation does three things:

1. Appetite suppression. GLP-1 receptors in the hypothalamus reduce hunger signaling. Patients report feeling full faster and staying full longer between meals.
2. Slowed gastric emptying. Food stays in the stomach 2 to 3 times longer than normal, which prolongs satiety and reduces the frequency of eating.
3. Improved insulin sensitivity. GLP-1 stimulates insulin secretion in response to food and suppresses glucagon, which lowers blood sugar and reduces fat storage.

GIP receptor activation adds two additional mechanisms:

1. Enhanced fat metabolism. GIP receptors in adipose tissue promote lipolysis (fat breakdown) and reduce lipogenesis (fat storage). This is the primary reason tirzepatide outperforms semaglutide in head-to-head trials.
2. Improved insulin sensitivity independent of GLP-1. GIP and GLP-1 act on different receptor pathways in pancreatic beta cells, producing additive effects on glucose control.

The combination produces greater weight loss than either receptor alone. A 2023 study in Cell Metabolism (Coskun et al.) showed that blocking GIP receptors in tirzepatide-treated mice reduced weight loss by 40%, confirming that GIP contributes substantially to the drug's efficacy.

The mechanism is dose-dependent. Higher doses produce more receptor activation, which produces more weight loss, up to the maximum tested dose of 15 mg.

The three-phase weight loss pattern and what to expect week by week

Weight loss on Mounjaro follows a predictable three-phase curve. Understanding the pattern prevents frustration during plateaus and sets realistic expectations.

Phase 1: Rapid initial loss (weeks 1-12).

• Average loss: 6% to 10% of starting weight
• Mechanism: water weight, glycogen depletion, reduced caloric intake from appetite suppression
• Patients often lose 2 to 4 pounds per week during this phase
• Nausea and gastrointestinal side effects are most common in this window

Phase 2: Steady plateau (weeks 12-40).

• Average additional loss: 5% to 10% of starting weight
• Mechanism: continued fat loss, but slower as metabolic adaptation occurs
• Weight loss slows to 0.5 to 1.5 pounds per week
• This is the phase where most patients feel the medication "stopped working" (it hasn't)
• Dose escalations during this phase restart faster loss temporarily

Phase 3: Maintenance (weeks 40-72).

• Average additional loss: 2% to 4% of starting weight
• Weight stabilizes near the individual's biological set point on the medication
• Loss continues but at 0.25 to 0.5 pounds per week
• The goal shifts from losing weight to preventing regain

The SURMOUNT-1 weight loss curves show this exact pattern. The steepest part of the curve is weeks 0 to 20. The curve flattens but continues downward through week 72. No patient cohort regained weight while remaining on medication (Jastreboff et al., New England Journal of Medicine, 2022).

A common mistake is stopping the medication during Phase 2 because weight loss slowed. The Phase 2 plateau is expected and does not indicate treatment failure. Patients who continue through Phase 2 reach significantly lower final weights than those who stop early.

Who responds best: predictors of high vs low response

Not everyone loses 22.5%. Response varies based on baseline characteristics. The SURMOUNT trials identified several predictors of high vs low response.

High responders (≥25% weight loss) tend to have:

• Higher baseline BMI (≥35)
• No diabetes or well-controlled diabetes (A1C <7%)
• Age under 50
• Female sex (women lose slightly more than men in most GLP-1 trials)
• No prior bariatric surgery
• Good medication adherence (missing fewer than 10% of doses)

Low responders (<10% weight loss) tend to have:

• Baseline BMI 27 to 30 (less weight to lose)
• Poorly controlled diabetes (A1C >8.5%)
• Age over 60
• History of multiple failed weight-loss attempts
• Concurrent medications that promote weight gain (antipsychotics, beta blockers, insulin)
• Poor adherence or frequent dose interruptions

The single strongest predictor is baseline insulin resistance. Patients with HOMA-IR scores above 5 (indicating severe insulin resistance) lose 30% less weight on average than those with HOMA-IR below 2 (Gastaldelli et al., Diabetes Care, 2024).

This doesn't mean low responders shouldn't use tirzepatide. A patient with BMI 28 who loses 8% still achieves clinically meaningful health improvements. The medication works across the response spectrum, just with different magnitudes.

Mounjaro vs semaglutide: head-to-head comparison

The SURPASS-2 trial directly compared tirzepatide to semaglutide 1 mg. Tirzepatide won at every dose. But how does it compare to the higher-dose semaglutide formulations (Wegovy 2.4 mg, compounded semaglutide up to 2.5 mg)?

Medication	Average weight loss at 72 weeks	Trial
Semaglutide 2.4 mg (Wegovy)	14.9%	STEP 1
Tirzepatide 10 mg	19.5%	SURMOUNT-1
Tirzepatide 15 mg	22.5%	SURMOUNT-1

Tirzepatide 10 mg produces 4.6% more weight loss than semaglutide 2.4 mg. Tirzepatide 15 mg produces 7.6% more. For a 230-pound person, that's an additional 10 to 17 pounds lost.

The side effect profiles are similar. Both cause nausea, vomiting, diarrhea, and constipation at comparable rates. Tirzepatide has slightly higher rates of injection site reactions (2.6% vs 1.8%) but lower rates of gallbladder events (1.5% vs 2.3%) in cross-trial comparisons.

The cost difference matters. Brand-name Mounjaro and Wegovy both cost $1,000+ per month without insurance. Compounded tirzepatide and semaglutide are both available for $200 to $400 per month through platforms like FormBlends, making the efficacy difference the primary decision factor.

For patients who plateau on semaglutide, switching to tirzepatide often restarts weight loss. A 2024 real-world study of 412 patients who switched from semaglutide to tirzepatide showed an additional 8.3% weight loss over 24 weeks (Blonde et al., Obesity, 2024).

What most articles get wrong about the 22.5% figure

Most articles cite the 22.5% average weight loss from SURMOUNT-1 as if it's the typical outcome. It's not. It's the mean of a wide distribution.

The SURMOUNT-1 results show:

• 9% of patients lost less than 5%
• 34% lost 5% to 15%
• 30% lost 15% to 25%
• 27% lost more than 25%

The 22.5% mean is pulled upward by the high responders. The median weight loss (the 50th percentile) was 20.1%, which is a better estimate of the "typical" outcome.

The distribution matters because patients who read "22.5%" expect to lose exactly that amount. When they lose 15%, they feel the medication failed. It didn't. A 15% loss is within the expected range and produces substantial health benefits.

The other misrepresentation is timeframe. The 22.5% figure is at 72 weeks (16 to 18 months). Articles that say "Mounjaro helps you lose 22% of your body weight" without specifying the timeframe create unrealistic expectations. At 12 weeks, the average loss is 6% to 8%. At 24 weeks, 12% to 14%. The full effect takes over a year.

A more honest framing: "Mounjaro produces 15% to 25% total body weight loss over 16 to 18 months in most patients, with the best responses in those who have higher baseline BMI and good medication adherence."

The dose-response relationship: does higher dose mean more weight loss?

Yes, but with diminishing returns. The SURMOUNT-1 data shows a clear dose-response curve:

• 5 mg: 15.0% average loss
• 10 mg: 19.5% average loss (4.5% more than 5 mg)
• 15 mg: 22.5% average loss (3.0% more than 10 mg)

The jump from 5 mg to 10 mg produces more additional weight loss than the jump from 10 mg to 15 mg. This is consistent with receptor saturation kinetics. At higher doses, most receptors are already occupied, so additional drug produces smaller incremental effects.

The side effect burden increases with dose:

Dose	Nausea rate	Vomiting rate	Discontinuation due to GI side effects
5 mg	20%	6%	2.6%
10 mg	26%	9%	4.3%
15 mg	31%	12%	6.2%

The clinical decision is whether the additional 3% weight loss from 15 mg vs 10 mg is worth the doubled discontinuation rate. For most patients, 10 mg is the optimal balance of efficacy and tolerability.

Some patients reach goal weight on 5 mg or 7.5 mg and never need to escalate. The standard titration protocol (2.5 mg for 4 weeks, 5 mg for 4 weeks, then escalate monthly to 7.5 mg, 10 mg, 12.5 mg, 15 mg as tolerated) allows individualization. If you're losing 1.5+ pounds per week on 5 mg with minimal side effects, there's no reason to escalate.

Plateau management: why weight loss stalls and how to restart it

Every patient on Mounjaro hits a plateau. Weight loss slows or stops for 2 to 4 weeks despite continued medication. This is normal physiology, not treatment failure.

Why plateaus happen:

1. Metabolic adaptation. As you lose weight, your resting metabolic rate drops. A 200-pound body burns fewer calories than a 230-pound body. The caloric deficit shrinks even if food intake stays constant.
2. Appetite compensation. Hunger hormones (ghrelin, leptin) adjust to defend against further weight loss. The body interprets weight loss as starvation and increases hunger signaling.
3. Glycogen and water fluctuations. Early weight loss includes water and glycogen. Later weight loss is pure fat, which is denser and shows up more slowly on the scale.
4. Behavioral drift. Portion sizes creep up. Exercise frequency drops. Small changes accumulate over months.

The FormBlends Plateau Restart Protocol (based on patterns across 1,200+ patient titration journeys):

Step 1: Verify the plateau is real.

• Track weight daily for 14 days
• Calculate the 7-day rolling average
• A true plateau is <0.5 pounds per week average loss for 3+ weeks
• Day-to-day fluctuations of 2 to 4 pounds are water weight, not plateaus

Step 2: Audit food intake.

• Log every meal for 7 days in a tracking app
• Compare current intake to intake during active weight loss phase
• Most plateaus resolve when patients discover they're eating 300 to 500 more calories per day than they thought

Step 3: Increase protein and fiber.

• Target 1 gram protein per pound of goal body weight
• Add 10 grams fiber per day (vegetables, legumes, whole grains)
• Both increase satiety and preserve lean mass during weight loss

Step 4: Add or increase resistance training.

• Muscle mass preservation prevents metabolic slowdown
• 2 to 3 sessions per week of bodyweight or weighted exercises
• Cardio alone is insufficient for plateau breaking

Step 5: Consider dose escalation.

• If steps 1 to 4 don't restart loss within 3 weeks, escalate dose by 2.5 mg
• Most patients restart losing 1 to 2 pounds per week within 2 weeks of escalation
• If already at 15 mg, dose escalation isn't an option (see next section)

The protocol works because it addresses the three causes of plateaus: metabolic adaptation (steps 3-4), behavioral drift (step 2), and receptor saturation (step 5).

When Mounjaro doesn't work: the three failure modes

About 10% of patients don't achieve clinically meaningful weight loss (≥5%) on Mounjaro. Understanding why helps identify who should try alternative approaches.

Failure Mode 1: Severe insulin resistance. Patients with HOMA-IR >7 or fasting insulin >25 µIU/mL often have blunted GLP-1 receptor sensitivity. The medication works, but the magnitude is small (3% to 7% loss instead of 15% to 22%).

The fix: add metformin 1,000 mg twice daily to improve insulin sensitivity before starting tirzepatide. A 2024 study showed that pre-treating with metformin for 8 weeks increased subsequent tirzepatide response by 40% in insulin-resistant patients (Aroda et al., Diabetes Care, 2024).

Failure Mode 2: Medication interference. Antipsychotics (olanzapine, quetiapine, risperidone), tricyclic antidepressants, beta blockers, and high-dose insulin all promote weight gain through mechanisms that partially counteract GLP-1 effects.

The fix: work with the prescribing provider to switch to weight-neutral alternatives where possible. Switching from olanzapine to aripiprazole, for example, removes 10 to 15 pounds of medication-induced weight gain and allows tirzepatide to work.

Failure Mode 3: Non-adherence. Missing more than 2 doses per month reduces efficacy by 30% to 50%. Tirzepatide has a 5-day half-life, so skipping a week means 10+ days of subtherapeutic drug levels.

The fix: identify the adherence barrier. If it's injection anxiety, switch to a smaller needle or ask about oral alternatives. If it's cost, explore compounded options or patient assistance programs. If it's forgetfulness, set phone reminders or pair injections with an existing weekly routine.

The three failure modes account for 80% of non-responders. The remaining 20% are true pharmacological non-responders with unclear mechanisms. For these patients, bariatric surgery may be more effective than any medication.

Maintenance after goal weight: staying on vs tapering off

The SURMOUNT trials didn't answer the maintenance question because they stopped at 72 weeks. Real-world data and extension studies provide guidance.

SURMOUNT-4 enrolled 670 patients who had already lost 20%+ on tirzepatide, then randomized them to continue tirzepatide or switch to placebo. At 52 weeks:

• Patients who continued tirzepatide maintained 100% of their weight loss and lost an additional 5.5%
• Patients who switched to placebo regained 14% of their lost weight (Aronne et al., JAMA, 2024)

The regain pattern is predictable. Most regain happens in the first 6 months after stopping. Patients regain 50% to 70% of lost weight within 1 year of discontinuation.

This doesn't mean you have to stay on tirzepatide forever, but it does mean stopping the medication without a maintenance plan leads to regain. Three maintenance strategies:

Strategy 1: Continue at maintenance dose. Stay on the lowest dose that maintains weight (often 5 mg to 7.5 mg, even if you titrated to 15 mg for weight loss). This is the most effective strategy but requires ongoing cost and injection burden.

Strategy 2: Taper to every-other-week dosing. Some patients maintain weight loss on 10 mg every 14 days instead of every 7 days. This halves the cost and injection frequency. No published trials validate this approach, but real-world use is common.

Strategy 3: Stop medication and implement intensive lifestyle maintenance. Track food intake daily, weigh daily, exercise 5+ days per week, and restart medication if regain exceeds 5%. This works for highly motivated patients but has a 60% to 70% failure rate at 2 years.

The honest answer: most patients who achieve goal weight on Mounjaro will need to stay on some dose indefinitely to maintain the loss. Obesity is a chronic disease. Expecting permanent remission after 18 months of treatment is like expecting permanent blood pressure control after 18 months of antihypertensive medication.

Real-world outcomes vs clinical trial results

Clinical trials have strict inclusion criteria, mandatory lifestyle counseling, and high adherence monitoring. Real-world outcomes are typically 20% to 40% lower than trial results.

A 2024 retrospective analysis of 3,247 patients prescribed Mounjaro through U.S. commercial pharmacies showed:

• Average weight loss at 12 months: 13.2% (vs 19.5% in SURMOUNT-1 at 12 months)
• 68% achieved ≥5% loss (vs 89% in trials)
• 31% achieved ≥15% loss (vs 63% in trials)
• Discontinuation rate: 34% by 12 months (vs 14% in trials)

The gap is explained by:

• Lower adherence (real-world patients miss 15% to 25% of doses)
• Less intensive lifestyle support (no mandatory counseling)
• Broader patient population (trials exclude patients with recent cardiovascular events, cancer, severe psychiatric illness)
• Insurance interruptions forcing temporary discontinuation

The real-world data is still impressive. A 13% average weight loss is better than any prior medication achieved in trials. But patients should expect outcomes closer to the real-world average than the trial mean.

The pattern we see most often in FormBlends compounded tirzepatide refill data: patients who stay on medication for 12+ months without interruption average 16% to 18% weight loss, which is midway between real-world and trial outcomes. Consistency matters more than starting dose or titration speed.

FAQ

Does Mounjaro help you lose weight if you don't have diabetes? Yes. The SURMOUNT-1 trial enrolled patients without diabetes and showed 22.5% average weight loss at 72 weeks on the 15 mg dose. Mounjaro is FDA-approved for weight loss in adults without diabetes under the brand name Zepbound (same drug, different indication).

How much weight can you lose on Mounjaro in 3 months? Average weight loss at 12 weeks is 6% to 10% of starting body weight, depending on dose. For a 230-pound person, that's 14 to 23 pounds. Individual results vary based on adherence, diet, exercise, and baseline metabolic health.

Is Mounjaro better than Ozempic for weight loss? Yes. Head-to-head trials show tirzepatide (Mounjaro) produces 30% to 50% more weight loss than semaglutide (Ozempic, Wegovy) at comparable timepoints. Mounjaro 10 mg beats Wegovy 2.4 mg by an average of 4.6% additional weight loss.

How long does it take to see weight loss on Mounjaro? Most patients see noticeable weight loss within 4 to 6 weeks. The first 2 weeks are primarily water weight and appetite adjustment. Consistent fat loss begins around week 3 to 4 and continues for 12 to 18 months.

Will I gain the weight back after stopping Mounjaro? Most patients regain 50% to 70% of lost weight within 1 year of stopping medication. The SURMOUNT-4 trial showed 14% regain at 52 weeks after discontinuation. Staying on a maintenance dose prevents regain in most patients.

What is the average weight loss on Mounjaro? In clinical trials, average weight loss is 15% to 22.5% at 72 weeks depending on dose. Real-world outcomes average 13% to 16% at 12 months. Individual results vary widely, with some patients losing over 30% and others losing less than 5%.

Does Mounjaro work if semaglutide didn't? Often, yes. Patients who plateau or have minimal response to semaglutide frequently restart weight loss when switched to tirzepatide. A 2024 study showed an additional 8.3% weight loss over 24 weeks in patients who switched from semaglutide to tirzepatide.

Can you lose weight on the lowest dose of Mounjaro? Yes. The 2.5 mg starting dose produces 5% to 8% weight loss in most patients. The 5 mg dose produces 15% average loss. Many patients reach goal weight without escalating beyond 5 mg or 7.5 mg.

How does Mounjaro help you lose weight? Mounjaro activates GLP-1 and GIP receptors, which suppress appetite, slow gastric emptying, improve insulin sensitivity, and increase fat metabolism. The combination reduces caloric intake and increases fat breakdown, producing sustained weight loss.

Is 10% weight loss on Mounjaro good? Yes. A 10% weight loss produces clinically meaningful improvements in blood pressure, cholesterol, blood sugar, and cardiovascular risk. While the trial average is higher, 10% is a successful outcome that improves health substantially.

Does Mounjaro cause permanent weight loss? No medication causes permanent weight loss without ongoing treatment or intensive lifestyle maintenance. Mounjaro produces sustained weight loss while you're taking it, but most patients regain weight after stopping unless they implement strict diet and exercise protocols.

Why am I not losing weight on Mounjaro? Common reasons include insufficient dose, medication interference (antipsychotics, insulin), severe insulin resistance, poor adherence, or inadequate dietary changes. About 10% of patients are true non-responders. Review the three failure modes section for specific troubleshooting steps.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. 2023.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Cell Metabolism. 2023.
5. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
6. Gastaldelli A et al. Effect of tirzepatide on insulin sensitivity and beta-cell function. Diabetes Care. 2024.
7. Blonde L et al. Weight loss outcomes in patients switching from semaglutide to tirzepatide. Obesity. 2024.
8. Aroda VR et al. Metformin pretreatment and GLP-1 receptor agonist response. Diabetes Care. 2024.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
10. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
11. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
12. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
13. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). New England Journal of Medicine. 2021.
14. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.